US6797274B1ExpiredUtility
Compounds
Est. expiryJan 22, 2019(expired)· nominal 20-yr term from priority
Inventors:Jean-Louis Ruelle
A61P 31/04C07K 14/22
76
PatentIndex Score
7
Cited by
16
References
10
Claims
Abstract
The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASBO47, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. An isolated, recombinant polypeptide comprising a member selected from the group consisting of
(a) the amino acid sequence SEQ ID NO:2;
(b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:2;
wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.
2. The isolated, recombinant polypeptide of claim 1 , wherein the polypeptide is according to (a).
3. The isolated, recombinant polypeptide of claim 1 , wherein the polypeptide is according to (b).
4. The isolated, recombinant polypeptide of claim 1 , wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.
5. The isolated recombinant polypeptide of claim 1 wherein the isolated polypeptide of (a) consists of SEQ ID NO:2.
6. A fusion protein comprising the isolated, recombinant polypeptide of claim 1 .
7. An immunogenic composition comprising the isolated, recombinant polypeptide of claim 1 and a pharmaceutically acceptable carrier.
8. The immunogenic composition of claim 7 , wherein the immunogenic composition comprises at least one other Neisseria meningitidis antigen in addition to an antigen provided by the polypeptide.
9. A method for inducing an immune response in a mammal comprising administration of the polypeptide of claim 1 .
10. An isolated polypeptide consisting of the amino acid sequence SEQ ID NO:2.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.